Century Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Century Therapeutics, Inc. on November 7, 2023. The filing discloses significant changes to the Company's executive leadership and Board of Directors, effective December 4, 2023.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive appointments and compensation arrangements.
Material Changes
- Appointment of CEO: Brent Pfeiffenberger was appointed President and Chief Executive Officer, effective December 4, 2023.
- Board Expansion: Dr. Pfeiffenberger was appointed to the Board of Directors, increasing the Board size to eight members.
- Role Transition: Gregory Russotti, Ph.D., will step down as Interim President and CEO to serve as Chief Technology and Manufacturing Officer.
Compensation and Management Commentary
The Board approved a comprehensive employment agreement for Dr. Pfeiffenberger, reflecting his over 20 years of global biopharmaceutical experience. Key compensation terms include:
- Base Salary: $625,000 annually.
- Bonuses: Annual performance-based target bonus of 55% of base salary; one-time signing bonus of $200,000; one-time retention bonus of $450,000.
- Equity Awards: Options to purchase 573,691 shares; 1,173,775 Restricted Stock Units (RSUs) with time-based vesting; and a second RSU award valued at a minimum of $450,000 vesting 100% on the first anniversary.
- Relocation: Reimbursement up to $150,000 for relocation expenses.
- Severance: In the event of termination without cause or resignation for good reason, Dr. Pfeiffenberger is entitled to 12 months of salary and COBRA continuation (extended to 18 months if near a change in control), plus accelerated vesting of time-based equity.
Dr. Russotti's new role as Chief Technology and Manufacturing Officer includes a base salary of $525,000 and an annual target bonus of 45%.
Investor Verification Checklist
- Verify the effective date of the leadership transition (December 4, 2023) and the interim period coverage.
- Review the full Employment Agreement for Dr. Pfeiffenberger, which will be filed as an exhibit to the 2023 Form 10-K.
- Confirm the vesting schedules and exercise prices for the equity awards granted to Dr. Pfeiffenberger.
- Assess the impact of the new CEO's background in commercial oncology on the Company's strategic direction.